ESR1 and breast carcinoma: In addition, the ER co-activator Mediator Subunit 1 (MED1) has been found to be a novel critical cross-talk point for the HER2 and ER signaling pathways within the cell and is amplified or overexpressed in more than 50% of all primary breast cancers[26,27].